UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): July 14, 2026
ALDEYRA THERAPEUTICS, INC.
(Exact name of Registrant as specified in its charter)
|
|
|
|
|
|
|
|
|
|
Delaware |
|
001-36332 |
|
20-1968197 |
(State or other jurisdiction of incorporation) |
|
(Commission File No.) |
|
(IRS Employer Identification No.) |
131 Hartwell Avenue, Suite 320
Lexington, MA 02421
(Address of principal executive offices and zip code)
Registrant’s telephone number, including area code: (781) 761-4904
Not Applicable
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
|
|
☐ |
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
|
|
☐ |
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
|
|
☐ |
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
|
|
☐ |
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
|
|
|
|
|
|
|
|
|
|
Title of each class |
|
Trading Symbol(s) |
|
Name of each exchange on which registered |
Common Stock, $0.001 par value per share |
|
ALDX |
|
The Nasdaq Stock Market LLC |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
On July 14, 2026, Aldeyra Therapeutics, Inc. (Aldeyra) received minutes (the Minutes) from a Type A meeting, held on June 10, 2026 with the U.S. Food and Drug Administration (FDA), regarding potential resubmission of the New Drug Application (NDA) of reproxalap for the treatment of dry eye disease. On July 15, 2026, Aldeyra requested a clarification of the Minutes from the FDA. In addition, Aldeyra intends to request a Type D meeting with the FDA to discuss potential resubmission of the NDA. The Type D meeting is expected to be held by the end of the third quarter of 2026.
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
|
|
|
|
|
ALDEYRA THERAPEUTICS, INC. |
|
|
By: |
|
/s/ Todd C. Brady |
Name: |
|
Todd C. Brady M.D., Ph.D. |
Title: |
|
Chief Executive Officer |
Dated July 15, 2026